Methylselenocysteine Promotes Etoposide Cytotoxicity by Enhancing Homotypic Gap Junctions Composed of Connexin 26

LYU Zhen-yu, JI Wen-bin, CHENG Qian-qian, ZHOU Xue-li, WANG Wei, YANG Yan

Abstract

 To investigate the effect of methylselenocysteine (MSC) on the function of homotypic gap junction (GJ) composed of connexin (Cx) 26 and its regulation of chemotherapeutic drug cytotoxicity.   Methods  The Tet-on HeLa cells transfected with and stably expressing Cx26 were used as the tool cells. Effects of MSC on cell growth, GJ function, and Cx26 protein expression were examined by MTT method, parachute assay, and Western blot analysis, respectively. The cytotoxicity of chemotherapeutic drugs was determined by standard colony-forming assay, and the relationship between MSC's effect on cytotoxicity of these chemotherapeutic drugs and its regulation of GJ was further analyzed.   Results  In Tet-on HeLa cells, doxycycline (Dox) can induce the expression of Cx26, which could then form functional GJs. Within a concentration range of 50 μmol/L, MSC had no significant effect on HeLa cell growth. Non-toxic concentrations of MSC can enhance GJs in a concentration-dependent manner and exert its effect at the nanomolar level. This effect was associated with an induction of Cx26 protein expression by MSC. Among the three common chemotherapeutic agents with different mechanisms of action, etoposide (Eto) presented cytotoxicity differences between HeLa cells cultured at low density (nonconfluent, no GJ formed) and high density (confluent, GJ formed). What's more, the inhibitory effect of Eto combined with MSC on HeLa cell colony formation was stronger than that of Eto alone, and this effect occurred only in HeLa cells with GJ formation.   Conclusion  MSC can potentiate the cytotoxicity of Eto by enhancing the GJs composed of Cx26, indicating that combined strategy of selenide and chemotherapy shows potential value in the treatment of malignant tumors.

 

Keywords: Methylselenocysteine, Connexin, Gap junction, Etoposide

 

Full Text:

PDF


References


NALEWAJSKA M， MARCHELEK-MYSLIWIEC M， OPARA-BAJEROWICZ M， et al. Connexins-therapeutic targets in cancers. Int J Mol Sci，2020，21(23): 9119. doi: 10.3390/ijms21239119.

MULKEARNS-HUBERT E E， REIZES O， LATHIA J D. Connexins in cancer: Jekyll or Hyde? Biomolecules，2020，10(12): 1654. doi: 10.3390/biom10121654.

NOGUEIRA C W， BARBOSA N V， ROCHA J B T. Toxicology and pharmacology of synthetic organoselenium compounds: an update. Arch Toxicol，2021，95(4): 1179–1226. doi: 10.1007/s00204-021-03003-5.

ZHOU X， LI M， CHENG Q， et al. Methylselenocysteine potentiates etoposide-induced cytotoxicity by enhancing gap junction activity. Biol Pharm Bull，2022，45(4): 467. doi: 10.1248/bpb.b21-00893.

BECKMANN A， HAINZ N， TSCHERNIG T， et al. Facets of communication: gap junction ultrastructure and function in cancer stem cells and tumor cells. Cancers (Basel)，2019，11(3): 288. doi: 10.3390/cancers11030288.

GRAHAM S V， JIANG J X， MESNIL M. Connexins and pannexins: important players in tumorigenesis, metastasis and potential therapeutics. Int J Mol Sci，2018，19(6): 1645. doi: 10.3390/ijms19061645.

ARORA S， HEYZA J R， CHALFIN E C， et al. Gap junction intercellular communication positively regulates cisplatin toxicity by inducing DNA damage through bystander signaling. Cancers (Basel)，2018，10(10): 368. doi: 10.3390/cancers10100368.

WU J I， WANG L H. Emerging roles of gap junction proteins connexins in cancer metastasis, chemoresistance and clinical application. J Biomed Sci，2019，26(1): 8. doi: 10.1186/s12929-019-0497-x.

GARCIA-RODRIGUEZ L， PEREZ-TORRAS S， CARRIO M， et al. Connexin-26 is a key factor mediating gemcitabine bystander effect. Mol Cancer Ther，2011，10(3): 505–517. doi: 10.1158/1535-7163.MCT-10-0693.

YANG J， QIN G， LUO M， et al. Reciprocal positive regulation between Cx26 and PI3K/Akt pathway confers acquired gefitinib resistance in NSCLC cells via GJIC-independent induction of EMT. Cell Death Dis， 2015，6(7): e1829. doi: 10.1038/cddis.2015.197.

GRAEBER S H， HULSER D F. Connexin transfection induces invasive properties in HeLa cells. Exp Cell Res，1998，243(1): 142–149. doi: 10. 1006/excr.1998.4130.

KOREEN I V， ELSAYED W A， LIU Y J， et al. Tetracycline-regulated expression enables purification and functional analysis of recombinant connexin channels from mammalian cells. Biochem J，2004，383(Pt1): 111–119. doi: 10.1042/BJ20040806.

AASEN T， LEITHE E， GRAHAM S V， et al. Connexins in cancer: bridging the gap to the clinic. Oncogene，2019，38(23): 4429–4451. doi: 10.1038/s41388-019-0741-6.

RAZAGHI A， POOREBRAHIM M， SARHAN D， et al. Selenium stimulates the antitumour immunity: insights to future research. Eur J Cancer，2021，155: 256–267. doi: 10.1016/j.ejca.2021.07.013.

ALI W， BENEDETTI R， HANDZLIK J， et al. The innovative potential of selenium-containing agents for fighting cancer and viral infections. Drug Discov Today，2021，26(1): 256–263. doi: 10.1016/j.drudis.2020.10. 014.

TAN H W， MO H Y， LAU A T Y， et al. Selenium species: current status and potentials in cancer prevention and therapy. Int J Mol Sci，2018， 20(1): 75. doi: 10.3390/ijms20010075.

BEHERA C， SANDHA K K， BANJARE N， et al. Implication of methylselenocysteine in combination chemotherapy with gemcitabine for improved anticancer efficacy. Eur J Pharm Sci，2022，176: 106238. doi: 10. 1016/j.ejps.2022.106238.

JINDAL S， CHOCKALINGAM S， GHOSH S S， et al. Connexin and gap junctions: perspectives from biology to nanotechnology based therapeutics. Transl Res，2021，235: 144–167. doi: 10.1016/j.trsl.2021.02. 008.

KIM S J， CHOI M C， PARK J M， et al. Antitumor effects of selenium. Int J Mol Sci，2021，22(21): 11844. doi: 10.3390/ijms222111844.

MARTINS-MARQUES T， RIBEIRO-RODRIGUES T， BATISTA-ALMEIDA D， et al. Biological functions of connexin43 beyond intercellular communication. Trends Cell Biol，2019，29(10): 835–847. doi: 10.1016/j.tcb.2019.07.001.

LIU H， YANG J， YANG W， et al. Focus on notoginsenoside R1 in metabolism and prevention against human diseases. Drug Des Devel Ther，2020，14: 551–565. doi: 10.2147/DDDT.S240511.

SAINI R K， KEUM Y S， DAGLIA M， et al. Dietary carotenoids in cancer chemoprevention and chemotherapy: a review of emerging evidence. Pharmacol Res，2020，157: 104830. doi: 10.1016/j.phrs.2020.104830.

CHEN Y， LI H， ZHANG G， et al. Synergistic inhibitory effect of resveratrol and TK/GCV therapy on melanoma cells. J Cancer Res Clin Oncol，2020，146(6): 1489–1499. doi: 10.1007/s00432-020-03203-z.

CHEN C X， LUO K J， YANG J P， et al. Connexins and cAMP cross-talk in cancer progression and metastasis. Cancers (Basel)，2020，13(1): 58. doi: 10.3390/cancers13010058.

TOFFOLI G， CORONA G， BASSO B， et al. Pharmacokinetic optimisation of treatment with oral etoposide. Clin Pharmacokinet，2004， 43(7): 441–466. doi: 10.2165/00003088-200443070-00002.


Refbacks

  • There are currently no refbacks.